Mitsudomi, Tetsuya

Institution/Organization
Kindai University Faculty of Medicine

Primary Specialty
Thoracic Surgery

Annual Disclosures & Policy Agreements
On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance
Understood

Disclosure of Potential Conflicts
Understood

**COI Disclosure**

**Disclosures**

AstraZeneca: advisory role, speaker fee
MSD: advisor role, speaker fee
Novartis: advisor role, speaker fee
Bristol Myers Squibb: advisor role, speaker fee
Ono: advisor role, speaker fee
Pfizer: advisor role, speaker fee
Boehringer Ingelheim: advisor role, speaker fee
Eli-Lilly: Speaker
Chugai: advisor role, speaker fee
Janssen:
Amgen: advisor role
Daiichi-Sankyo: advisory role
Taiho: advisor, speaker
INVITAE: speaker role
Bayer: speaker
Thermofisher: speaker advisor

**COI Disclosure Certification**

Disclosed

**Confidentiality Agreement**

Agree

**Standards of Conduct Agreement**

Agree

**IASLC’s Tax-Exempt Status**

Agree

**COI Follow-Up**

Disclose any clinical trials you are conducting for institution fees.

Aegean CheckMate 816 Keynote-091 BR.31

Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.

President, The Japan Lung Cancer Society 2014-2018
Board of Director, Japanese Society of Medical Oncology 2013-2019 Coard of Director, Japanese Association for Chest Surgery 2013-2019

**Have you received any personal fees from any outside accreditation entities such as CME companies?**

No

**Are you conducting clinical trials with any oncology equipment companies?**

No